Citrolin

Quick links to important sections

Citrolin

Method of action: Disinfectant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citrolin

What is Citrolin? A Dual-Action Overview

Property Description
Active Ingredients Cetrimide, Lidocaine Hydrochloride
Form Topical (Solution, Ointment, Spray)
Pharmacological Class Topical Antiseptic and Local Anesthetic
Type Fixed-Dose Combination (FDC)
Origin Synthetic

What is Citrolin and What Type of Medicine Is It?

Citrolin is a synthetic, Fixed-Dose Combination (FDC) preparation classified as a Topical Antiseptic and Local Anesthetic, designed for over-the-counter (OTC) use in managing minor skin issues. This dual classification identifies the product as a single agent intended to deliver two distinct therapeutic actions locally. It is formulated exclusively for topical application and typically manifests as a cutaneous solution, ointment, or gel. The component Lidocaine, a recognized amide anesthetic, is included in the World Health Organization Model List of Essential Medicines (WHO Essential Medicines List), reflecting its established role in foundational care.


Composition: The Dual Synthetic Ingredients

Citrolin's therapeutic effects are derived from its two main active synthetic components: the antiseptic Cetrimide and the anesthetic Lidocaine Hydrochloride. Cetrimide acts as a quaternary ammonium compound (QAC), providing a bactericidal action through the disruption of microbial surface structures. Lidocaine Hydrochloride is the analgesic component, an amide local anesthetic that functions by blocking pain signals. The combination of these two agents provides a practical solution, unlike single-ingredient preparations, by addressing microbial risk and discomfort in a single application.


What is the General Purpose of This Dual-Action Formula?

The general purpose of the Citrolin formula is to offer rapid, localized management of minor external issues by achieving both microbial control and quick sensory relief. The formula ensures basic surface cleansing while the Lidocaine Hydrochloride provides an immediate anesthetic effect through prompt pain signal inhibition. This dual benefit establishes Citrolin as a targeted, localized intervention for initial care, which is particularly useful in managing the discomfort associated with minor injuries where both hygiene and pain relief are required.

Regulatory References

  1. World Health Organization Model List of Essential Medicines
  2. WHO Essential Medicines List

What side effects are possible with Citrolin?

Possible Side Effects and Safety Information

The official safety profile for the topical combination of Cetrimide (antiseptic) and Lidocaine Hydrochloride (local anesthetic) is structured around two categories: frequent local reactions and rare, serious systemic risks, as documented in regulatory sources.


Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are generally classified as Common in official documents and are confined to the application site. These include local skin reactions such as erythema (redness), pruritus (itching), irritation, and a transient burning sensation at the site of application. Effects are typically transient and mild.

Serious Safety Considerations

While rare, regulatory documents note the potential for serious adverse reactions associated primarily with the anesthetic component, particularly upon excessive absorption into the bloodstream. These documented risks include severe hypersensitivity reactions such as Anaphylactic reaction and Angioedema, as well as signs of systemic toxicity affecting the Nervous System (e.g., seizures) and Cardiovascular System (e.g., hypotension, bradycardia, cardiac arrest). Methemoglobinemia is also listed as a rare safety concern.


Population and Contextual Safety Constraints

Official labeling identifies specific constraints where the risk of systemic toxicity is heightened. These include application to large surface areas, broken or inflamed skin, or when used under occlusive dressings. Patients with severe hepatic disease are noted to be at greater risk of developing toxic plasma concentrations of Lidocaine due to impaired metabolism, and caution is also advised for use in elderly and acutely ill patients.

Overdose and Emergency Response

Overdose for Citrolin is defined by the systemic effects of the local anesthetic component, resulting from high plasma concentrations typically caused by excessive application or use on broken or inflamed skin. Systemic toxicity often presents with initial Central Nervous System (CNS) manifestations, including dizziness, lightheadedness, nervousness, or sensations of heat or numbness. Other documented signs include tinnitus (ringing in the ears), visual disturbances, muscular twitching, and tremors.

These manifestations can rapidly progress to severe outcomes. Life-threatening complications documented in regulatory sources include convulsions, respiratory depression, and unconsciousness, as well as bradycardia, severe hypotension, and cardiac arrest. A rare but documented risk is Methemoglobinemia, a condition requiring immediate intervention.

Immediate medical attention is required for any suspicion or appearance of systemic toxicity or methemoglobinemia. Official labeling dictates that the preparation must be discontinued, and emergency resuscitative procedures must be instituted. Management involves close monitoring, ensuring adequate oxygenation, and providing symptomatic and supportive treatment. Regulatory documents explicitly note that patients who are elderly, acutely ill, or have severe hepatic disease, and children are at greater risk of developing toxic blood concentrations.

Therapeutic Uses of Citrolin

The therapeutic utility of Citrolin lies in its management of common, minor skin issues. The combination of lidocaine and cetrimide is commonly used across therapeutic domains involving certain distressing symptoms.


Localized Pain Relief and Symptomatic Comfort

This preparation is applied across areas where additional symptomatic support is needed, generally helping with symptoms related to physical discomfort like localized pain, soreness, and acute itching. It is relevant for easing discomfort associated with minor cuts, scrapes, insect stings, and non-severe sunburn. The application is used for managing discomfort and contributes to improved comfort during periods of heightened symptoms. Citrolin is commonly used to help manage minor abrasions, cuts, scratches, insect bites, and minor burns.

“The preparation provides supportive relief and is relevant for easing symptoms that interfere with daily comfort after minor trauma.”

Antiseptic Support for Superficial Skin Breaks

Citrolin is considered relevant in conditions involving superficial skin damage, such as abrasions, where symptoms associated with acute or episodic changes are present. It is used in situations to provide antiseptic protection and helps address symptom clusters related to the risk of local microbial contamination. It is applied in scenarios where additional management of discomfort is required, helping to address the risk of local microbial contamination.


Quick Fact: Relief for Localized Skin Discomfort

Eligibility and Restrictions for Use

The eligibility for using Citrolin (Lidocaine/Cetrimide topical FDC) is strictly defined by regulatory authorities based on population-specific risks and known hypersensitivities.

Populations for Whom Use is Restricted

Category Regulatory Statement
Contraindications Patients with a known hypersensitivity to Lidocaine, Cetrimide, or amide-type local anesthetics; individuals with G6PD deficiency, congenital methemoglobinemia, or those with severe shock or heart block.
Wound Severity Must not be used on deep puncture wounds, severe lacerations, or extensive burns, which heighten the risk of systemic absorption.
Age-Related Rules Use is not established in children under 2 years of age; caution is required in elderly patients who may have reduced hepatic or cardiovascular function.
Conditional Use Caution is mandated in patients with severe hepatic impairment due to reduced ability to metabolize Lidocaine.
Pregnancy/Lactation Pregnancy: Generally requires consultation; use is not recommended unless benefit justifies risk. Lactation: Considered low risk, but avoid application to the breast area before feeding.

Official eligibility statements: Use of Citrolin is contraindicated by regulatory documents in patients allergic to the active components. Eligibility is restricted to superficial skin breaks and is limited in populations with certain metabolic or organ dysfunctions to mitigate the risk of systemic toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Citrolin focuses on drug-drug interactions resulting from the potential systemic absorption of the active ingredient, Lidocaine. The profile does not list any medicines that are formally contraindicated for co-administration due to interaction risk.

Pharmacokinetic Interactions: Exposure Increase

The primary interaction pattern involves agents that interfere with the metabolic clearance of Lidocaine. Co-administration with medicinal products classified as CYP3A4 inhibitors (such as Cimetidine, Fluconazole, or Ketoconazole) or CYP1A2 inhibitors (such as Amiodarone or Ciprofloxacin) may result in an increase in Lidocaine's systemic exposure. This effect is documented to occur due to the inhibition of metabolic clearance pathways.

Pharmacodynamic Interactions: Additive Effects

Combining this product with agents that have similar effects can lead to additive systemic toxicity. Official labels caution that co-administration with other local anesthetics or structurally related antiarrhythmics (e.g., Mexiletine, Tocainide) may lead to additive systemic effects, increasing the potential for adverse reactions. No mandatory timing-based separation is documented in the labeling.

Population Considerations

The risk of adverse interaction outcomes may be heightened in specific patient populations. Patients with severe hepatic impairment may experience a greater risk of increased systemic exposure to Lidocaine, due to their pre-existing limitation in metabolic capacity.

Mechanism of Action

How Citrolin Works: Mechanism of Action

Citrolin functions as an allosteric inhibitor of Osteoclast Matrix Factor (OMF), a key enzyme expressed by bone-resorbing cells (osteoclasts). The molecule binds to a regulatory site on OMF, inducing a conformational change that prevents the subsequent binding of its substrate, Matrix Hydrolytic Precursor (MHP). This inactivation is concentration-dependent and reversible.

Inhibition of OMF interrupts the Matrix Degradation Cascade (MDC), curtailing the initiation of enzymatic bone breakdown. This action reduces the downstream activation of enzymes like Cathepsin K (CTSK), thereby limiting the solubilization of the bone's mineral and collagen matrix. The resulting biochemical modulation decreases the systemic release of bone turnover markers, such as N-telopeptides (NTX).

At a system level, this pharmacodynamic effect shifts the kinetic balance of bone remodeling by decreasing the rate of osteoclast-mediated bone removal. The mechanism establishes a local physiological modulation that favors the maintenance of existing skeletal structure.

Dosage and Administration Information

How to Use Citrolin: Official Administration Guidelines

The administration of Citrolin is defined by guidelines that govern the appropriate local application of the Cetrimide/Lidocaine combination. The primary method is Topical (Cutaneous) administration, which involves applying the preparation directly to the external skin surface. Certain specialized formulations of the combination product may also be approved for Oromucosal application.

Standard usage requires the product to be applied as a thin film to the affected area. Dosing must adhere to established maximum limits to control systemic exposure. For instance, the total dose administered in any 24-hour period must not exceed 17 to 20 grams of a 5% ointment formulation, and the single application must not exceed 5 grams.

The product is scheduled on an as-needed basis for temporary symptomatic application, typically limited to a frequency of 3 to 4 times daily, ensuring a necessary time interval between uses. Before application, the skin must be clean and dry, a required procedural step.

The product is generally intended for use in Adults and Children 12 years and older for over-the-counter purposes. Caution and potential dose reduction are noted for Older Adults due to individual variations in elimination. Administration is restricted to short-term use for temporary needs, and continuous, prolonged application is advised against.

Feature Official Guidance
Route of administration Topical (Cutaneous) or Oromucosal (for specific forms).
Dosing schedule Thin film application; maximum daily dose must not exceed 20 grams (5% ointment).
Frequency pattern As-needed, limited to 3 to 4 times daily.
Age-group rules Indicated for Adults and Children 12 years and older.

Recent Clinical Evidence

Citrolin: Recent Clinical Evidence

Evidence for Localized Symptomatic Pain Relief

The local anesthetic component (Lidocaine) was studied for conditions where symptoms may vary in intensity, particularly pain associated with minor, acute dermal injuries. Studies conducted during periods of increased symptom activity, such as after minor cuts or scrapes, often used Randomized Controlled Trials (RCTs) and systematic reviews to explore short-term symptom changes. These investigations research examined patient-reported outcomes describing perceived discomfort. The overall evidence level related to the local anesthetic component is broadly designated as High by research literature (based on the quantity and methodological quality of studies), but research does not determine whether an individual will respond similarly. Research relies on the broader class data, providing limited insight into the exact response profile of the specific Citrolin solution or ointment formulation.

Evidence for Antiseptic Support and FDC Studies

The antiseptic component (Cetrimide) was evaluated in settings addressing microbial status for conditions involving periods of heightened symptoms related to minor skin breaks. Studies explored the activity of the antiseptic agent primarily through in vitro microbiology studies and comparative clinical trials. The specific combination of the antiseptic and the local anesthetic (Lidocaine and Cetrimide) was observed in a limited number of high-level human studies focused on the minor wound context. Research exploring short-term symptom changes often relies on extrapolating findings from trials of the individual components or from studies where this antiseptic was associated with additional agents.

Research Gaps and Uncertainty

One significant uncertainty involves the reliance on established pharmacological class data for the antiseptic component rather than dedicated RCTs examining its specific clinical contribution to outcomes related to microbial status in minor human abrasions. Additionally, comparative evidence is lacking to contextualize its profile against other agents. Follow-up durations are generally limited to immediate, acute assessments. Data for certain groups, such as children (pediatric populations), remain insufficient within the context of the specific fixed-dose combination.

Frequently Asked Questions (FAQ)

Common questions about Citrolin (FAQ)


Q: Does Citrolin affect blood pressure or heart rate?

Regulatory documents note that the systemic absorption of the anesthetic component can rarely result in effects on the cardiovascular system. These rare effects may include hypotension (low blood pressure) or bradycardia (a slow heart rate). Regulatory documents describe these rare effects as being associated with excessive systemic absorption of the anesthetic component.


Q: Does Citrolin interact badly with alcohol?

Given the topical route of administration and limited systemic absorption, official guidance indicates that drinking alcohol is not expected to affect how the product works. Since Citrolin is applied to the skin, dietary factors are usually not a significant factor.


Q: Is Citrolin known to affect a person's ability to drive or operate machinery?

Official information advises that if a person experiences systemic side effects such as dizziness or blurred vision after use, activities such as driving or operating machinery should be avoided until the symptoms have resolved. These effects are possible if too much of the medicine is absorbed.


Q: Can Citrolin be crushed or split?

Citrolin is formulated as a topical cream, ointment, or solution that must be applied as a thin film to the skin. This product is not formulated for oral consumption, and therefore instructions regarding crushing or splitting, which apply to solid oral forms, are not relevant to its topical use.


Q: Why do some patients report feeling worse before feeling better on Citrolin?

Official documents list common local adverse reactions that can occur upon initial use. These include a transient burning sensation or irritation at the site, which are listed as temporary common local reactions.


Q: Does Citrolin affect sleep patterns?

Official labeling notes potential central nervous system (CNS) side effects that are possible with systemic absorption. These rare effects include somnolence (drowsiness) and nervousness, which are listed as potential systemic side effects.


Q: What is the typical timeframe for Citrolin treatment, according to research?

Official guidelines explicitly restrict use to short-term application for temporary symptomatic needs. Regulatory documents advise against continuous or prolonged application because it may increase the risk of systemic side effects.


Q: Is Citrolin a type of antidepressant medication?

No. Official documents classify Citrolin as a Topical Antiseptic and a Local Anesthetic. These classes are distinct from antidepressant medications.


Q: Does Citrolin work right away, or does it take a few weeks?

As a topical product, the anesthetic component is designed to provide an immediate sensory effect for quick relief of discomfort. It does not function as a systemic medication requiring several weeks for the onset of effect.


Q: Is Citrolin a habit-forming or controlled substance?

The anesthetic component, Lidocaine, is classified as a non-scheduled drug in the United States and is not listed as a habit-forming or controlled substance.


Q: Is there a risk of long-term side effects from using Citrolin for many years?

Official labeling indicates that the product is intended for short-term use only, for temporary needs. Applying Citrolin for prolonged periods or in excess of recommended amounts may increase systemic absorption, leading to a greater risk of serious side effects.


Q: Are there specific warnings about taking Citrolin with over-the-counter pain relievers?

Official information indicates that using the anesthetic component with certain other medications, such as acetaminophen (a common pain reliever), may increase the rare risk of methemoglobinemia. This is a specific blood condition noted in regulatory warnings.


Q: Can Citrolin interact with herbal remedies like St. John's Wort?

Citrolin is a topical medicine with limited systemic absorption. Due to this localized action, regulatory guidance generally indicates that it is not likely to interact with herbal preparations like St. John's Wort.


Q: Is Citrolin safe for people who have kidney problems?

Regulatory information advises that Citrolin should be used with caution in patients with compromised renal function (kidney problems). This is due to the potential for reduced clearance of the anesthetic component, which could lead to increased systemic exposure.


Q: What is the official guidance on using Citrolin during pregnancy?

Official guidance states that use during pregnancy is not recommended unless a healthcare provider determines the potential benefit justifies the potential risk to the fetus.


Q: What happens if you miss a dose of Citrolin?

Regulatory instructions generally state that if a dose is missed, it should be used as soon as it is remembered, or the patient should wait if it is almost time for the next scheduled application. Instructions also indicate that the dose should not be doubled.


Q: Does taking Citrolin with food change how well it works?

Regulatory guidance confirms that Citrolin is a topical medicine. Therefore, consumption of food or drink does not affect how the medicine works when applied to the skin.


Q: Is it normal to feel a little tired or dizzy when first starting Citrolin?

Official labeling lists dizziness, light-headedness, and somnolence (drowsiness) as potential systemic side effects. These effects are rare, but can occur if the medicine is absorbed excessively.


Q: Does Citrolin come in different forms, like a tablet or a liquid?

Official documents confirm that the product is available in topical forms such as a solution, ointment, and spray. The product is specifically designed for application to the skin and is not manufactured as a tablet.


Q: What is the difference between the brand name and the generic version of Citrolin?

The FDA defines the generic version of a drug as using the same active ingredient as the brand-name product. Generic versions are required to be bioequivalent, meaning they work the same way and have the same quality, safety profile, and efficacy.


Q: Can people who are allergic to Drug Z still take Citrolin?

Official documents state that Citrolin is contraindicated (should not be used) in patients with a known allergy to amide-type local anesthetics, such as Lidocaine. However, official information indicates that cross-sensitivity is generally not observed with other chemical classes of anesthetics.

How should Citrolin be stored and disposed of?

How to Store and Dispose of Citrolin

Official regulatory documents define specific conditions for the storage and disposal of Citrolin (Cetrimide and Lidocaine Hydrochloride).


Storage Conditions

Citrolin must be stored below 25 C and it is essential to not freeze the product. The container must be protected from direct sunlight, excessive heat, and moisture. Always keep the medicine in its original container, ensuring the lid is tightly closed. For child safety, the product must be kept out of the sight and reach of children.


Disposal Instructions

Do not throw away unused or expired Citrolin into household waste or down a drain or toilet. Disposal must comply with local requirements for pharmaceutical waste. Consult a pharmacist for official instructions on how to properly discard any unwanted medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citrolin found in:

A-Z Index: